Various
carcinogens induce EGFR/RAS/MAPK signaling, which is critical in the development of
lung cancer. In particular, constitutive activation of
extracellular signal-regulated kinase 2 (ERK2) is observed in many
lung cancer patients, and therefore developing compounds capable of targeting ERK2 in lung
carcinogenesis could be beneficial. We examined the
therapeutic effect of
catechol in
lung cancer treatment.
Catechol suppressed anchorage-independent growth of murine KP2 and human H460
lung cancer cell lines in a dose-dependent manner.
Catechol inhibited ERK2
kinase activity in vitro, and its direct binding to the ERK2 active site was confirmed by X-ray crystallography. Phosphorylation of c-Myc, a substrate of ERK2, was decreased in
catechol-treated
lung cancer cells and resulted in reduced protein stability and subsequent down-regulation of total c-Myc. Treatment with
catechol induced G1 phase arrest in
lung cancer cells and decreased
protein expression related to G1-S progression. In addition, we showed that
catechol inhibited the growth of both allograft and xenograft
lung cancer tumors in vivo. In summary,
catechol exerted inhibitory effects on the ERK2/c-Myc signaling axis to reduce
lung cancer tumor growth in vitro and in vivo, including a preclinical patient-derived xenograft (PDX) model. These findings suggest that
catechol, a natural small molecule, possesses potential as a novel therapeutic agent against lung
carcinogenesis in future clinical approaches.